Doximity Acquires Pathway to Boost AI Clinical Tools & Datasets
Doximity, Inc., the leading digital platform for U.S. medical professionals, has significantly expanded its artificial intelligence capabilities through the acquisition of Pathway Medical Inc. The $63 million deal, finalized on July 29, 2025, integrates Montreal-based Pathway’s specialized medical AI and evidence-based clinical reference tools into Doximity’s existing suite of offerings.
Pathway brings to Doximity a unique blend of clinical expertise and technological innovation. Notably, physicians constitute half of Pathway’s team, a composition that has been instrumental in the company’s development of one of medicine’s most comprehensive structured datasets. Over seven years, this team meticulously compiled data purpose-built for AI, encompassing virtually every significant medical guideline, pharmaceutical, and landmark clinical trial across all major specialties. This meticulous approach has yielded an AI model that demonstrates superior clinical accuracy, evidenced by a remarkable 96% score on the U.S. Medical Licensing Examination (USMLE) benchmark.
The acquisition is poised to dramatically enhance Doximity’s clinical reference tools, a prospect that has excited both companies. Jeff Tangney, co-founder and CEO of Doximity, expressed his enthusiasm, stating that Pathway’s painstakingly built dataset would elevate Doximity’s capabilities to an entirely new level. Pathway’s existing user base, comprising hundreds of thousands of registered individuals and thousands who pay $300 annually for premium access, underscores the demand for its sophisticated tools. Jon Hershon, CEO of Pathway, highlighted the growing need for clinical instruments that seamlessly combine trusted evidence with the agility and speed of AI. He emphasized that partnering with Doximity, a highly trusted platform in healthcare, would enable Pathway to bring its valuable experience to millions of medical professionals for free, directly integrated into the tools they already use at the point of care.
The financial terms of the transaction included a cash consideration of $26 million, supplemented by up to $37 million in additional equity grants, totaling the $63 million valuation. This strategic acquisition signifies Doximity’s commitment to leveraging advanced AI to empower medical professionals, streamlining access to critical information and supporting more informed clinical decisions across the healthcare landscape.